We compared tau burden measured by PET, brain volume assessed by magnetic resonance imaging (MRI), cross-sectional cognitive function, longitudinal cognitive decline, and polygenic risk score (PRS) between PET/plasma groups. The gene discussed is MAPT; the disease is Mental deterioration.